Literature DB >> 18192944

The relationship between erectile dysfunction and cardiovascular disease. Part I: pathophysiology and mechanisms.

Vishal Kapur1, Ernst R Schwarz.   

Abstract

There is increased awareness regarding the close association between cardiovascular disease and erectile dysfunction, especially because both conditions share common risk factors such as diabetes mellitus, hypertension, smoking, hyperlipidemia, and a sedentary lifestyle. Recent studies suggest that erectile dysfunction could be considered a potential marker for underlying silent cardiac or vascular disease processes. Endothelial dysfunction seems to play a major role in both sexual dysfunction and heart disease. With the initiation in 1998 of vasoactive drugs such as the phosphodiesterase-5 inhibitors for the treatment of erectile dysfunction, the underlying vascular components of erectile dysfunction have become a more prominent focus of attention in the clinical and research setting. This review critically examines the background, pathophysiology, and mechanisms behind erectile dysfunction and its close correlation to cardiovascular disease.

Entities:  

Mesh:

Year:  2007        PMID: 18192944

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  5 in total

1.  Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction.

Authors:  S La Vignera; R Condorelli; E Vicari; R D'Agata; A E Calogero
Journal:  J Endocrinol Invest       Date:  2011-11       Impact factor: 4.256

2.  Molecular targets for diabetes mellitus-associated erectile dysfunction.

Authors:  Elizabeth Yohannes; Jinsook Chang; Moses T Tar; Kelvin P Davies; Mark R Chance
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

3.  Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study.

Authors:  Katelynn M Wilton; Sara J Achenbach; Paras Karmacharya; Floranne C Ernste; Eric L Matteson; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2020-10-15       Impact factor: 5.346

4.  Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Dioma U Udeoji; Ernst R Schwarz
Journal:  Clin Med Insights Case Rep       Date:  2014-11-19

5.  Sexual Activity in Heart Failure Patients: Information Needs and Association with Health-Related Quality of Life.

Authors:  Anneleen Baert; Sofie Pardaens; Delphine De Smedt; Paolo Emilio Puddu; Maria Costanza Ciancarelli; Amos Dawodu; Johan De Sutter; Dirk De Bacquer; Els Clays
Journal:  Int J Environ Res Public Health       Date:  2019-05-05       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.